Eddie Pharmaceuticals: Application for clinical trial of ACC085 injection was accepted.

Eddie Pharmaceuticals announced that the company and its wholly-owned subsidiary, Lushui Eddie Pharmaceutical Technology Co., Ltd., recently received the "Acceptance Letter" for the registration clinical trial of domestically produced drugs issued by the National Medical Products Administration. The product, ACC085 injection, is indicated for pre-exposure prevention of HIV-1 cloth shell inhibitors in adults and adolescents weighing at least 35 kg at risk of HIV-1 infection.